Hospital
Adventhealth Polk North INC
Adventhealth Polk North INC was paid $15.43M by Medicaid between Jan 2018 and Dec 2024, across 201 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoADVENTHEALTH POLK NORTH INC
DAVENPORT, FL 33837
DAVENPORT, FL 33837
33aNPI1801457510assigned 06/24/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.43M
24GClaims532,808
24DCodes billed201
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#28 of 163
Median peer was paid$4.77M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 35,752 | $432K | |
| 2019 | 100,950 | $2.06M | |
| 2020 | 80,992 | $1.83M | |
| 2021 | 102,873 | $3.21M | |
| 2022 | 102,263 | $3.23M | |
| 2023 | 71,500 | $2.89M | |
| 2024incomplete | 38,478 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 39,749 | 36,098 | $3.55M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 32,481 | 28,473 | $2.71M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 10,834 | 9,315 | $714K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.3% | 4,989 | 4,242 | $668K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 3,193 | 2,847 | $584K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 8,146 | 7,235 | $583K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.8% | 8,048 | 6,832 | $580K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.3% | 5,272 | 1,571 | $511K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.3% | 3,523 | 3,086 | $504K |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 11,873 | 8,240 | $428K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.5% | 5,483 | 4,778 | $385K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.5% | 4,971 | 4,305 | $384K |
189 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 14,707 | $344K |
| 59025 | Fetal non-stress test | 1.9% | 1,957 | $287K |
| 80053 | Comprehensive metabolic panel | 1.3% | 28,332 | $207K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,153 | $163K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 2,126 | $155K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 3,070 | $155K |
| 84703 | <1% | 13,176 | $143K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,535 | $138K |
| 80306 | <1% | 3,817 | $135K | |
| 87070 | <1% | 5,337 | $130K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,926 | $105K |
| G0378 | Hospital observation service, per hour | <1% | 3,606 | $84K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 425 | $79K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,271 | $76K |
| 86850 | <1% | 2,112 | $73K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,610 | $71K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,741 | $66K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 9,706 | $61K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,863 | $60K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 155 | $59K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 299 | $56K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,592 | $53K |
| 86900 | <1% | 2,739 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,626 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,654 | $41K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 580 | $39K |
| 92650 | <1% | 985 | $38K | |
| 01999 | <1% | 2,368 | $38K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,614 | $36K |
| 73630 | <1% | 938 | $35K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,871 | $31K |
| 84702 | <1% | 2,325 | $29K | |
| 83880 | <1% | 2,850 | $28K | |
| 81003 | <1% | 9,049 | $28K | |
| 73610 | <1% | 818 | $26K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,032 | $26K |
| 72100 | <1% | 1,109 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,537 | $22K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 832 | $22K |
| 85610 | <1% | 5,956 | $22K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,217 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,374 | $21K |
| 82947 | <1% | 2,575 | $20K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 823 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 33,224 | $19K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 95 | $18K |
| 93976 | <1% | 540 | $17K | |
| 81001 | <1% | 13,750 | $16K | |
| 73130 | <1% | 378 | $16K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 585 | $16K |
| 97161 | <1% | 254 | $15K | |
| 76801 | <1% | 1,674 | $15K | |
| 73030 | <1% | 805 | $15K | |
| 87420 | <1% | 338 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 425 | $14K |
| 84484 | <1% | 9,052 | $13K | |
| 74018 | <1% | 846 | $12K | |
| 73560 | <1% | 432 | $12K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 933 | $12K |
| 73562 | <1% | 636 | $11K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 674 | $10K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 3,328 | $10K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 204 | $9K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 495 | $9K |
| 43235 | <1% | 13 | $8K | |
| 80061 | Lipid panel | <1% | 1,366 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 168 | $8K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 59 | $8K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 619 | $7K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 74 | $7K |
| 82948 | <1% | 467 | $6K | |
| 73110 | <1% | 299 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 218 | $6K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 136 | $6K |
| 85730 | <1% | 4,929 | $5K | |
| 82962 | <1% | 1,415 | $5K | |
| 96376 | <1% | 2,049 | $5K | |
| 93971 | <1% | 393 | $5K | |
| 97597 | <1% | 67 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 112 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,201 | $4K |
| 12001 | <1% | 73 | $4K | |
| 87077 | <1% | 837 | $3K | |
| A4649 | Surgical supply; miscellaneous | <1% | 17 | $3K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 20 | $3K |
| 72131 | <1% | 140 | $3K | |
| 87210 | <1% | 617 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 562 | $3K |
| 87807 | <1% | 472 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 852 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,884 | $3K |
| 72040 | <1% | 334 | $3K | |
| 74022 | <1% | 445 | $3K | |
| 83735 | <1% | 4,440 | $3K | |
| 74019 | <1% | 102 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,705 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,725 | $2K |
| 83690 | <1% | 7,908 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,707 | $2K |
| 94761 | <1% | 1,992 | $2K | |
| 87040 | <1% | 1,775 | $2K | |
| 92587 | <1% | 70 | $2K | |
| 80050 | General health panel | <1% | 486 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,780 | $2K |
| 12011 | <1% | 74 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,294 | $2K |
| 86901 | <1% | 2,716 | $2K | |
| 85379 | <1% | 2,391 | $2K | |
| 97162 | <1% | 15 | $2K | |
| 85027 | <1% | 1,597 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 69 | $1K |
| 76830 | Ultrasound, transvaginal | <1% | 98 | $1K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 21 | $1K |
| 72050 | <1% | 40 | $1K | |
| 94664 | <1% | 469 | $1K | |
| 70486 | <1% | 14 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,391 | $1K |
| 82077 | <1% | 450 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 842 | $927.08 |
| 87186 | <1% | 1,288 | $926.59 | |
| 73140 | <1% | 25 | $915.53 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,305 | $866.58 |
| 76870 | <1% | 15 | $838.62 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,113 | $822.15 |
| 97116 | <1% | 208 | $794.65 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $746.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,090 | $739.80 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 836 | $737.72 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 235 | $728.14 |
| 36600 | <1% | 34 | $669.94 | |
| 73080 | <1% | 48 | $660.12 | |
| 83605 | <1% | 733 | $646.90 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,363 | $627.29 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 477 | $564.06 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,627 | $469.19 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,884 | $452.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 952 | $383.48 |
| 85652 | <1% | 449 | $353.87 | |
| 94762 | <1% | 181 | $319.47 | |
| 84550 | <1% | 14 | $282.71 | |
| 73502 | <1% | 60 | $271.79 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 17 | $257.56 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 156 | $240.00 |
| 82553 | <1% | 193 | $222.41 | |
| 82550 | <1% | 428 | $222.23 | |
| 85651 | <1% | 393 | $177.96 | |
| 85007 | <1% | 299 | $174.31 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 265 | $172.36 |
| 82803 | <1% | 74 | $164.10 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 159 | $160.12 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,123 | $159.21 |
| 87088 | <1% | 349 | $133.32 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 850 | $125.17 |
| 93970 | <1% | 15 | $113.25 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 364 | $75.46 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 771 | $64.02 |
| 73590 | <1% | 13 | $56.81 | |
| 84439 | <1% | 102 | $55.38 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $25.22 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $23.63 |
| 87205 | <1% | 64 | $17.22 | |
| 99152 | <1% | 37 | $13.87 | |
| 81025 | <1% | 237 | $10.50 | |
| 90714 | <1% | 45 | $10.00 | |
| 86140 | <1% | 206 | $6.05 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 190 | $5.04 |
| 80349 | 0% | 125 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 1,781 | $0.00 |
| C1769 | Guide wire | 0% | 109 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 20 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 132 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 127 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 58 | $0.00 |
| 94760 | 0% | 59 | $0.00 | |
| 88304 | 0% | 15 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 78 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 21 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 56 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 129 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 15 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 444 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 91 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 310 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 140 | $0.00 |
| 82570 | 0% | 50 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 16 | $0.00 |
| 84100 | 0% | 27 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 22 | $0.00 |
| 90715 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENGESBACH, ALAN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Adventhealth Polk South INC | Lake Wales, FL | $7.13M |
| Adventhealth Polk South INC | Lake Wales, FL | $447K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.